TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31532358

Group type: EXPERIMENTAL
Intervention: Non-invasive weaning (NIV)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Invasive weaning
Number of subjects: 364
Study: 28691581

Group type: EXPERIMENTAL
Intervention: 10‐min showering at ∼40°C before lights out
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal sleeping conditions (control)
Number of subjects: 11
Study: 26117212

Group type: EXPERIMENTAL
Intervention: NLP plus health education
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 23982674

Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 0
Study: 21762268

Group type: EXPERIMENTAL
Intervention: PBMT7 (pantoprazole 40 mg twice daily, metronidazole 500 mg thrice daily, bismuth subcitrate 300 mg and tetracycline 500 mg four times daily for 7 days)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: PBMT14 (pantoprazole 40 mg twice daily, metronidazole 500 mg thrice daily, bismuth subcitrate 300 mg and tetracycline 500 mg four times daily for 14 days)
Number of subjects: 199
Study: 19995253

Group type: EXPERIMENTAL
Intervention: Absorbable subcuticular sutures (polyglytone 6211, Caprosyn)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-absorbable interrupted sutures (polybutester, Novafil)
Number of subjects: 47
Study: 17259206

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg orally
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 14679326

Group type: EXPERIMENTAL
Intervention: Buffered ibuprofen (800 mg ibuprofen + 200 mg magnesium hydroxide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ibuprofen (800 mg ibuprofen)
Number of subjects: 20
Study: 11694865

Group type: EXPERIMENTAL
Intervention: Oral Disease Preventive Protocol including oral physiotherapy, non-alcoholic 0.05% fluoride mouthwashes, and topical application of myconazole oral gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Instructions on oral physiotherapy
Number of subjects: 12
Study: 9503766

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral techniques
Number of subjects: 19
Study: 8056235

Group type: EXPERIMENTAL
Intervention: Biliary stents with side-holes (SH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Biliary stents without side-holes (NSH)
Number of subjects: 70
Study: 3134468

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg with aspirin 1 g
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Aspirin 1 g
Number of subjects: 8
Study: 30070379

Group type: EXPERIMENTAL
Intervention: Mailed outreach plus patient navigation
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Mailed outreach alone
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Usual care with visit-based screening
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Mailed outreach groups (both outreach and outreach/navigation)
Number of subjects: 1800
Study: 28969399

Group type: EXPERIMENTAL
Intervention: Open end ureteral catheter insertion prior to PNL
Number of subjects: 50

Group type: COMPARATOR
Intervention: No catheter insertion prior to PNL
Number of subjects: 50
Study: 26228589

Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: In-office balloon dilation
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standalone balloon dilation
Number of subjects: 135
Study: 24433565

Group type: EXPERIMENTAL
Intervention: Interactive Guided Imagery (IGI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Digital storytelling (DS)
Number of subjects: 35
Study: 21915653

Group type: EXPERIMENTAL
Intervention: Fatigued participants
Number of subjects: 202

Group type: COMPARATOR
Intervention: Alert participants
Number of subjects: 202
Study: 19755574

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: General Psychiatric Management (GPM)
Number of subjects: 180
Study: 17688398

Group type: EXPERIMENTAL
Intervention: Exercise Plus Program
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Exercise Only
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Plus Only (motivation)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 209
Study: 15051743

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (500 mg bid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11806481

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose Plus with phosphoric acid and Z100
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scotchbond 1 after etching with phosphoric acid plus Z100
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: F2000 with its Primer/Adhesive
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intact incisors (Group D)
Number of subjects: 30
Study: 10193283

Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supine horizontal position
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hammock position
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trendelenburg position (after 90 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supine horizontal position (after 90 min)
Number of subjects: 60
Study: 8113843

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (120 mg/m2 IV on day 1)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Moderate-dose cisplatin (30 mg/m2 IV on days 2 and 3) and carboplatin (200 mg/m2 IV on day 1)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Moderate-dose cisplatin and carboplatin
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin
Number of subjects: 109
Study: 3288695

Group type: EXPERIMENTAL
Intervention: 125 micrograms cyclopenthiazide
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 500 micrograms cyclopenthiazide
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 50 micrograms cyclopenthiazide
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 68
Study: 31931887

Group type: EXPERIMENTAL
Intervention: Transactional Analysis (TA) group-training, 8 sessions of 90 minutes each.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 76
Study: 31155577

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (MgO) co-administration
Number of subjects: 0
Study: 26018671

Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg bolus followed by 0.25 mg/kg/h infusion)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg bolus followed by 0.3 μg/kg/h infusion)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 66
Study: 25244801

Group type: EXPERIMENTAL
Intervention: Adaptation training (sitting, walking, running in hot lab)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anti-dizzy training (revolving chair training for 10 times)
Number of subjects: 60
Study: 23730989

Group type: EXPERIMENTAL
Intervention: Patients aged 65 years and older
Number of subjects: 32

Group type: COMPARATOR
Intervention: Patients younger than 65 years
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with longer duration of hypertension
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with lower basal metabolic index
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with diabetes or chronic kidney disease
Number of subjects: 32
Study: 20648203

Group type: EXPERIMENTAL
Intervention: Local anesthetic only (Group I)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Local anesthetic mixed with non-particulate betamethasone (Group II)
Number of subjects: 70
Study: 18037603

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (Project CHAT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study: 16309554

Group type: COMPARATOR
Intervention: Transpupillary therapy (TTT) alone (Group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (iTA) 4 mg followed by TTT (Group B)
Number of subjects: 26
Study: 14615619

Group type: EXPERIMENTAL
Intervention: Mean maximum CIMT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean common CIMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups from published RCTs
Number of subjects: 0
Study: 11093285

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (3.3 microg/(kg min))
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Insulin (1 mU/(kg min))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 6
Study: 8875584

Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline sulfate
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline sulfate
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 1.0 mg terbutaline sulfate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 8444205

Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Ventilation
Number of subjects: 40
Study: 3770037

Group type: EXPERIMENTAL
Intervention: Peptichemio, Vincristine and prednisone (PTC‐VCR‐P)
Number of subjects: 75

Group type: COMPARATOR
Intervention: melphalan and prednisone (MPH‐P)
Number of subjects: 75
Study: 29732549

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg QD
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Eslicarbazepine acetate (ESL) 400 mg QD
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Patients not from Western Europe (WE)
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Patients not taking carbamazepine (CBZ) at baseline
Number of subjects: 1351
Study: 24297950

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg once weekly
Number of subjects: 512

Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice per day
Number of subjects: 512
Study: 22459771

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (1,600 μg/d)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 20201749

Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Losartan (LOS)
Number of subjects: 27
Study: 17905275

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 101

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 101
Study: 16033593

Group type: EXPERIMENTAL
Intervention: Preoperative nursing intervention for pain
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine care only (Control)
Number of subjects: 62
Study: 12161519

Group type: COMPARATOR
Intervention: Saline/Saline infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline/GHRH infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhGH infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study: 10334442

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (1, 10, 100, and 1,000 microg/min for 5 min each)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Benazeprilat (25 microg/min) during adenosine infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sodium nitroprusside (n = 4)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acetylcholine (n = 4)
Number of subjects: 18
Study: 7624461

Group type: EXPERIMENTAL
Intervention: Brief psychotherapy with a religious perspective (15-20 sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (brief psychotherapy without religious perspective)
Number of subjects: 32
Study: 2568803

Group type: EXPERIMENTAL
Intervention: Ionic contrast medium (sodium meglumine diatrizoate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium (iopromide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 61394

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 250 mug suspended in methyl ethyl cellulose ('Tylose') 6% solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tylose alone
Number of subjects: 30
Study: 30783061

Group type: EXPERIMENTAL
Intervention: Healthy old group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Healthy young group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Psoriasis and atopic dermatitis groups
Number of subjects: 20
Study: 27324934

Group type: EXPERIMENTAL
Intervention: Buccal infiltration of local anaesthesia (LA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Palatal injections of 0.1 ml 2% lidocaine with 1:100,000 adrenaline
Number of subjects: 50
Study: 25968966

Group type: EXPERIMENTAL
Intervention: Sodium picosulfate and magnesium citrate (PMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 0
Study: 23292288

Group type: EXPERIMENTAL
Intervention: 10-g testosterone gel daily for 6 months
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 20192950

Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR genotype (L'L' vs S' allele) in males
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR genotype (S'S' vs L' alleles) in females
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR genotype (1 L' allele vs 2 L' alleles) in females
Number of subjects: 862
Study: 19269837

Group type: EXPERIMENTAL
Intervention: Coseal sealant (CG)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Suture/stapling (SCG)
Number of subjects: 203
Study: 16551902

Group type: EXPERIMENTAL
Intervention: Paravertebral blocks (PVB)
Number of subjects: 50
Study: 12760869

Group type: EXPERIMENTAL
Intervention: Indinavir 1,200 mg q12h
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Indinavir 1,000 mg q8h
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg q24h
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Efavirenz 300 mg q12h
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Abacavir 300 mg q12h
Number of subjects: 36
Study: 10580184

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 809

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 809
Study: 9085461

Group type: EXPERIMENTAL
Intervention: Hemoccult II test (HII)
Number of subjects: 6366

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 6366

Group type: EXPERIMENTAL
Intervention: Positive HII test
Number of subjects: 6366

Group type: EXPERIMENTAL
Intervention: Post-examination
Number of subjects: 6366

Group type: EXPERIMENTAL
Intervention: One year after work-up
Number of subjects: 6366
Study: 8334889

Group type: EXPERIMENTAL
Intervention: 0.5 mg norethisterone (NET) per day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.5 mg norethisterone (NET) per day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3.0 mg norethisterone (NET) per day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 3552837

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1386
Study: 30216086

Group type: EXPERIMENTAL
Intervention: ALIS + GBT
Number of subjects: 336

Group type: COMPARATOR
Intervention: GBT alone
Number of subjects: 336
Study: 26876692

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) treatment, mean blood concentration at V1: 660 ng/ml, at V2: 1020 ng/ml, mean difference 366 units, p < 0.001
Number of subjects: 166
Study: 26011959

Group type: EXPERIMENTAL
Intervention: Multifocal IOL (ZAM00 group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Accommodative IOL (FLEX group)
Number of subjects: 112
Study: 22192095

Group type: EXPERIMENTAL
Intervention: +POWER
Number of subjects: 7
Study: 20542472

Group type: EXPERIMENTAL
Intervention: DuraSeal Xact Adhesion Barrier and Sealant System (DSX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (local standard of care)
Number of subjects: 20
Study: 18562131

Group type: COMPARATOR
Intervention: TPH1 (Reference AA)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: TPH1 (AC)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: TPH1 (CC)
Number of subjects: 792

Group type: COMPARATOR
Intervention: 5‐HTTLPR (Reference LL)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SL)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SS)
Number of subjects: 792

Group type: COMPARATOR
Intervention: HTR1A (Reference CC)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: HTR1A (CG)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: HTR1A (GG)
Number of subjects: 792

Group type: COMPARATOR
Intervention: 5‐HTTLPR (Reference LL) at 12-week follow-up
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SL) at 12-week follow-up
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SS) at 12-week follow-up
Number of subjects: 792

Group type: COMPARATOR
Intervention: 5‐HTTLPR (Reference LL) at 26-week follow-up
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SL) at 26-week follow-up
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SS) at 26-week follow-up
Number of subjects: 792
Study: 16202353

Group type: EXPERIMENTAL
Intervention: fentanyl 2 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: esmolol 2 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 60
Study: 12733727

Group type: EXPERIMENTAL
Intervention: 8-month whole body vibration (4 min/day, 3-5 times per week, oscillating from 25 to 45 Hz)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 10546921

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg once daily for 5 days)
Number of subjects: 11
Study: 8913195

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 1862217

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (600 LRU daily for 12 weeks)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 7178704

Group type: EXPERIMENTAL
Intervention: 4% lidocaine aerosol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline aerosol
Number of subjects: 12
Study: 30601950

Group type: EXPERIMENTAL
Intervention: Dolutegravir monotherapy 50 mg once daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Continuation of cART
Number of subjects: 101
Study: 29691526

Group type: EXPERIMENTAL
Intervention: Black pepper-based beverage (BPB) preload containing 20 mg gallic acid equivalent (GAE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 16
Study: 26315860

Group type: EXPERIMENTAL
Intervention: Colchicine (administered for 3 months after an initial 3 months of observation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no intervention for 6 months)
Number of subjects: 18
Study: 24699032

Group type: EXPERIMENTAL
Intervention: Subtherapeutic dosages of cyclosporin A (CsA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditioned stimulus (CS) without CsA
Number of subjects: 0
Study: 22832147

Group type: EXPERIMENTAL
Intervention: Behavior change communication intervention
Number of subjects: 959

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 959
Study: 19202050

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17496414

Group type: EXPERIMENTAL
Intervention: 5-FU/LV followed by CPT-11
Number of subjects: 120

Group type: COMPARATOR
Intervention: CPT-11 followed by 5-FU/LV
Number of subjects: 120
Study: 15498188

Group type: EXPERIMENTAL
Intervention: Spasfon (80 mg intravenously)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Atropine (0.5 mg injected into the cervix)
Number of subjects: 97
Study: 11848259

Group type: EXPERIMENTAL
Intervention: Very-low-dose perindopril-indapamide combination
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Intensive modified-release gliclazide-based glucose control regimen
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Usual guidelines-based treatment
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 10000
Study: 9865735

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA) therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RA therapy after relapse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chemotherapy after relapse
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CRABP‐II mRNA levels in RA relapse cases
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RA protein binding activity in RA relapse cases
Number of subjects: 36
Study: 7833225

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of an aqueous solution containing paracetamol, salicylate, diclofenac, and [125I]-albumin (0.1 to 0.2 ml)
Number of subjects: 5
Study: 3122349

Group type: EXPERIMENTAL
Intervention: Mannitol (preoperative administration)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No Mannitol (control group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 31
Study: 29068724

Group type: EXPERIMENTAL
Intervention: Online intervention targeting young adults for improving dietary choices
Number of subjects: 68
Study: 26959498

Group type: EXPERIMENTAL
Intervention: Tai chi group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 100
Study: 24461900

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 2 weeks
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 4 weeks
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 22623266

Group type: EXPERIMENTAL
Intervention: 2 mg risperidone
Number of subjects: 80